| scholarly article | Q13442814 |
| P2093 | author name string | Jing Wang | |
| Diansheng Zhong | |||
| Ruili Han | |||
| P2860 | cites work | Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth | Q40105523 |
| Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival | Q40272854 | ||
| Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. | Q40478257 | ||
| Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide | Q41197059 | ||
| LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition | Q43188970 | ||
| Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer | Q44513206 | ||
| Expression of LKB1 tumor suppressor in non-small cell lung cancer determines sensitivity to 2-deoxyglucose | Q46102008 | ||
| Cyclooxygenase 2 inhibitors and lung carcinoma | Q46495532 | ||
| Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model | Q46637543 | ||
| [Advances of LKB1-AMPK-mTOR Signaling Pathway in Tumor]. | Q54566377 | ||
| Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas | Q77827931 | ||
| Deforolimus (AP23573) a novel mTOR inhibitor in clinical development | Q82623944 | ||
| Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy | Q21198871 | ||
| Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. | Q24540159 | ||
| Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors | Q24614112 | ||
| The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress | Q24633606 | ||
| Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell | Q28208372 | ||
| The LKB1-AMPK pathway: metabolism and growth control in tumour suppression | Q29617506 | ||
| LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling | Q34279063 | ||
| Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer | Q34281221 | ||
| Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells | Q36573268 | ||
| Targeting AMPK: a new therapeutic opportunity in breast cancer | Q37110916 | ||
| In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. | Q39979957 | ||
| The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. | Q40021818 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | Chinese | Q7850 |
| P304 | page(s) | 435-438 | |
| P577 | publication date | 2012-07-01 | |
| P1433 | published in | Chinese Journal of Lung Cancer | Q26842043 |
| P1476 | title | [Progress of related targets in LKB1 signaling pathway for non-small cell lung cancer therapy]. | |
| P478 | volume | 15 |
| Q49958922 | Role of Hippo Signaling Pathway in Lung Cancer | cites work | P2860 |
Search more.